Literature DB >> 27080466

Growth Modulation of Diabetic Factors and Antidiabetic Drugs on Prostate Cancer Cell Lines.

Shiaw-Wen Chien1, Dong-Yih Kuo2, Jiuan-Miaw Liao2, Paulus S Wang3,4,5,6,7, Ching-Han Yu8,9.   

Abstract

Risk factors for prostate cancer (PCa) include age, hormones, race, family history and diet. Recently, epidemiologic evidence has indicated that history of diabetes mellitus (DM) is inversely associated with risk of PCa. However, epidemiological investigations have yielded inconsistent results. Hence, the exact mechanism of DM-induced reduction in the incidence of PCa has yet to be fully elucidated. The aim of this study was to investigate the effects of DM factors, including glucose, insulin and insulin-like growth factor-1 (IGF-1), on the proliferation of PCa cell lines in vitro. Cell proliferation and expression of hormone receptors was examined in MTT assay and Western blot analysis, respectively. The results showed that DM factors did not affect the viability of androgen receptor (AR)-expressing PCa cell lines. However, cell proliferation increased after treatment with DM factors in androgen-independent PCa cell lines. On PCa tissue arrays, intensities of total AR and nuclear IGF-1R were higher in malignant tissues than in normal prostate glands. In terms of hormonal receptors, androgen-dependent LNCaP cells treated with insulin and IGF-1 in a low-serum medium showed decreased expression of insulin receptor beta (IRβ) and elevated expression of IGF-1 receptor beta (IGF-1Rβ). Moreover, expression of AR was upregulated after insulin and IGF-1 treatment in LNCaP cells, but not in the other PCa cell lines. Most of the studied antidiabetic drugs promoted the viability of PCa cells. However, metformin decreased the viability of AR-expressing PCa cells. These results suggest that diabetic factors modify the expression of AR, IR and IGF-1R to increase cancer cell proliferation. Moreover, the growth suppressing effects of metformin on PCa may be via the regulation of the AR signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27080466     DOI: 10.4077/CJP.2016.BAE368

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  3 in total

Review 1.  The anticancer potential of metformin on prostate cancer.

Authors:  Saher Zaidi; Jason Gandhi; Gunjan Joshi; Noel L Smith; Sardar Ali Khan
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-01-16       Impact factor: 5.554

2.  SUMO-modified insulin-like growth factor 1 receptor (IGF-1R) increases cell cycle progression and cell proliferation.

Authors:  Yingbo Lin; Hongyu Liu; Ahmed Waraky; Felix Haglund; Prasoon Agarwal; Helena Jernberg-Wiklund; Dudi Warsito; Olle Larsson
Journal:  J Cell Physiol       Date:  2017-04-25       Impact factor: 6.384

Review 3.  Metformin: A Bridge between Diabetes and Prostate Cancer.

Authors:  Veronica Zingales; Alfio Distefano; Marco Raffaele; Antonio Zanghi; Ignazio Barbagallo; Luca Vanella
Journal:  Front Oncol       Date:  2017-10-11       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.